AssetMark Inc’s Immunocore IMCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$102K Sell
3,213
-25,174
-89% -$745K ﹤0.01% 1619
2026
Q1
$856K Sell
28,387
-3,289
-10% -$106K ﹤0.01% 1065
2025
Q4
$1.1M Sell
31,676
-2,393
-7% -$84.5K ﹤0.01% 997
2025
Q3
$1.24M Sell
34,069
-889
-3% -$30.2K ﹤0.01% 927
2025
Q2
$1.1M Buy
34,958
+1,248
+4% +$38.8K ﹤0.01% 904
2025
Q1
$1M Buy
33,710
+1,539
+5% +$46.2K ﹤0.01% 866
2024
Q4
$949K Buy
32,171
+1,616
+5% +$51.1K ﹤0.01% 859
2024
Q3
$951K Buy
30,555
+1,878
+7% +$68.3K ﹤0.01% 785
2024
Q2
$972K Buy
28,677
+7,031
+32% +$359K ﹤0.01% 781
2024
Q1
$1.41M Buy
21,646
+3,666
+20% +$252K ﹤0.01% 652
2023
Q4
$1.23M Buy
17,980
+6,969
+63% +$362K ﹤0.01% 631
2023
Q3
$571K Buy
11,011
+3,902
+55% +$231K ﹤0.01% 730
2023
Q2
$426K Buy
7,109
+6,223
+702% +$355K ﹤0.01% 752
2023
Q1
$43.8K Buy
886
+278
+46% +$15.6K ﹤0.01% 1061
2022
Q4
$34.7K Buy
608
+297
+95% +$16.7K ﹤0.01% 1116
2022
Q3
$15K Buy
311
+92
+42% +$4.38K ﹤0.01% 1176
2022
Q2
$8K Buy
219
+125
+133% +$4.06K ﹤0.01% 1242
2022
Q1
$3K Buy
+94
New +$2.37K ﹤0.01% 1361

Other funds holding IMCR

AssetMark Inc's IMCR Position: Q2 2026 in Review

AssetMark Inc reduced its Immunocore (IMCR) stake by 89% in Q2 2026, selling an estimated $745K and leaving 3,213 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #1619.

AssetMark Inc first reported a position in IMCR in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.41M in Q1 2024. 21 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • AssetMark Inc held 3,213 shares of Immunocore worth $102K as of Q2 2026.
  • AssetMark Inc sold 25,174 Immunocore shares in Q2 2026, an estimated $745K.
  • Immunocore made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1619 holding.
  • AssetMark Inc first reported a position in Immunocore in Q1 2022 and has held it in 18 quarters since.
  • AssetMark Inc's Immunocore position peaked at $1.41M in Q1 2024.
  • 21 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.